Cargando…
Tofacitinib as a novel therapy in COVID-19 acute respiratory distress syndrome
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Wolters Kluwer - Medknow
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8613470/ https://www.ncbi.nlm.nih.gov/pubmed/34908570 http://dx.doi.org/10.4103/ija.ija_817_21 |
| _version_ | 1784603648065536000 |
|---|---|
| author | Panda, Rajesh Singh, Pooja Kodamanchili, Saiteja Anand, Abhijeet |
| author_facet | Panda, Rajesh Singh, Pooja Kodamanchili, Saiteja Anand, Abhijeet |
| author_sort | Panda, Rajesh |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8613470 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Wolters Kluwer - Medknow |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-86134702021-12-13 Tofacitinib as a novel therapy in COVID-19 acute respiratory distress syndrome Panda, Rajesh Singh, Pooja Kodamanchili, Saiteja Anand, Abhijeet Indian J Anaesth Clinical Communication Wolters Kluwer - Medknow 2021-10 2021-10-28 /pmc/articles/PMC8613470/ /pubmed/34908570 http://dx.doi.org/10.4103/ija.ija_817_21 Text en Copyright: © 2021 Indian Journal of Anaesthesia https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. |
| spellingShingle | Clinical Communication Panda, Rajesh Singh, Pooja Kodamanchili, Saiteja Anand, Abhijeet Tofacitinib as a novel therapy in COVID-19 acute respiratory distress syndrome |
| title | Tofacitinib as a novel therapy in COVID-19 acute respiratory distress syndrome |
| title_full | Tofacitinib as a novel therapy in COVID-19 acute respiratory distress syndrome |
| title_fullStr | Tofacitinib as a novel therapy in COVID-19 acute respiratory distress syndrome |
| title_full_unstemmed | Tofacitinib as a novel therapy in COVID-19 acute respiratory distress syndrome |
| title_short | Tofacitinib as a novel therapy in COVID-19 acute respiratory distress syndrome |
| title_sort | tofacitinib as a novel therapy in covid-19 acute respiratory distress syndrome |
| topic | Clinical Communication |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8613470/ https://www.ncbi.nlm.nih.gov/pubmed/34908570 http://dx.doi.org/10.4103/ija.ija_817_21 |
| work_keys_str_mv | AT pandarajesh tofacitinibasanoveltherapyincovid19acuterespiratorydistresssyndrome AT singhpooja tofacitinibasanoveltherapyincovid19acuterespiratorydistresssyndrome AT kodamanchilisaiteja tofacitinibasanoveltherapyincovid19acuterespiratorydistresssyndrome AT anandabhijeet tofacitinibasanoveltherapyincovid19acuterespiratorydistresssyndrome |